VAD regimen
WikiDoc Resources for VAD regimen |
Articles |
---|
Most recent articles on VAD regimen Most cited articles on VAD regimen |
Media |
Powerpoint slides on VAD regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on VAD regimen at Clinical Trials.gov Clinical Trials on VAD regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on VAD regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on VAD regimen Discussion groups on VAD regimen Patient Handouts on VAD regimen Directions to Hospitals Treating VAD regimen Risk calculators and risk factors for VAD regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for VAD regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:VAD Regimen; Vincristine-Adriamycin-Dexamethasone Regimen
Overview
VAD regimen refers to a regimen consisting of vincristine, doxorubicin (adriamycin) and dexamethasone used as induction treatment for multiple myeloma.[1][2]
Regimen
VVincristine ADoxorubicin (Adriamycin) DDexamethasone
Indications
References
- ↑ "NCI Thesaurus".
- ↑ 2.0 2.1 Wan J (2013). "[Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma]". Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21 (3): 647–9. doi:10.7534/j.issn.1009-2137.2013.03.022. PMID 23815915.
- ↑ "NCI Thesaurus".